Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Assets Average (2021 - 2025)

Vivos Therapeutics has reported Assets Average over the past 5 years, most recently at $25.4 million for Q4 2025.

  • Quarterly Assets Average rose 65.83% to $25.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.4 million through Dec 2025, up 65.83% year-over-year, with the annual reading at $20.2 million for FY2025, 55.44% up from the prior year.
  • Assets Average was $25.4 million for Q4 2025 at Vivos Therapeutics, down from $25.8 million in the prior quarter.
  • Over five years, Assets Average peaked at $43.6 million in Q3 2021 and troughed at $10.5 million in Q4 2023.
  • The 5-year median for Assets Average is $17.4 million (2022), against an average of $21.4 million.
  • Year-over-year, Assets Average plummeted 57.01% in 2022 and then soared 65.83% in 2025.
  • A 5-year view of Assets Average shows it stood at $37.4 million in 2021, then tumbled by 57.01% to $16.1 million in 2022, then plummeted by 34.47% to $10.5 million in 2023, then soared by 45.54% to $15.3 million in 2024, then soared by 65.83% to $25.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Assets Average are $25.4 million (Q4 2025), $25.8 million (Q3 2025), and $18.7 million (Q2 2025).